Bristol-Myers Squibb Company (BMY)
Bristol Myers Squibb (BMY) Surpasses Market Returns: Some Facts Worth Knowing
Bristol Myers Squibb (BMY) closed at $54.19 in the latest trading session, marking a +1.61% move from the prior day.
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
BMY Gains 13.1% in Three Months: Buy, Sell or Hold the Stock?
BMY shares are rebounding after a strong Q3, lifted by rising demand for Opdivo, Reblozyl and Camzyos, even as legacy drugs face generic pressure.
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
Bristol Myers Squibb (BMY) closed the most recent trading day at $52.41, moving +2.36% from the previous trading session.
Can Opdivo's Label Expansions Help Bristol Myers Sustain Its Momentum?
BMY gets a priority FDA review for Opdivo's use in previously untreated advanced Hodgkin lymphoma, reinforcing its oncology momentum.
Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call Transcript
Bristol-Myers Squibb Company (BMY) Shareholder/Analyst Call Transcript
5 Blue Chip Stocks to Buy Now That Pay Reliable 4%+ Dividends
Investors love high-yield dividend stocks, especially the blue chip variety, because they offer a significant income stream and have massive total return potential.
Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?
Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.
Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales?
Bristol Myers gains FDA approval to expand Breyanzi's label to R/R marginal zone lymphoma, strengthening its CAR T portfolio amid rising sales.
Bristol-Myers Squibb Company (BMY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Bristol-Myers Squibb Company (BMY) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
BMY Gains on News of Continuation of Alzheimer's Disease Study
Bristol Myers jumps after choosing to continue its phase III ADEPT-2 study on Cobenfy for Alzheimer-related psychosis, delaying data to next year.
